Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
Condition: Rhinoconjunctivitis; Rhinitis; Conjunctivitis; Allergy
MeSH terms: Rhinitis; Conjunctivitis
Study type: Interventional
Phase: Phase 3

Summary: 
      The purpose of the study is to investigate the efficacy and safety of a grass sublingual
      tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis
      with or without asthma.
    

Detailed description: 
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in
      participants aged 5 to <18 years of either sex, and of any race with a history of grass
      pollen induced rhinoconjunctivitis with or without asthma. While receiving treatment,
      participants will receive either grass sublingual tablet or placebo. Open-label rescue
      medications for the rhinoconjunctivitis and asthma symptoms will be provided. Participants
      will visit the study site for at least 12 visits. A total of 10 allergic symptoms, 6
      rhinoconjunctivitis and 4 lung symptoms, will be recorded daily on an electronic diary by the
      participant/parent/guardian.

      The start and end of the grass pollen season (GPS) was determined based on the regional grass
      pollen count, and lasted up to 162 days. For each region, the GPS is defined as the first day
      of 3 consecutive recorded days with a grass pollen count of ≥ 10 grains/m^3, to the last day
      of the last occurrence of 3 consecutive recorded days with a grass pollen count ≥ 10
      grains/m^3, inclusively.
    

Intervention name(s): Placebo; SCH 697243; Loratadine Syrup 1 mg/mL Rescue Treatment; Loratadine 10 mg Rescue Treatment; Olopatadine 0.1% Rescue Treatment; Mometasone furoate 50 mcg Rescue Treatment; Albuterol 108 mcg Rescue Treatment; Fluticasone 44 mcg Rescue Treatment; Prednisone 5 mg Rescue Treatment
Intervention type(s): Drug; Biological; Drug; Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): Placebo sublingual tablet, once daily; Grass sublingual tablet, once daily; Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to <6 years of age and at a dose of 10 mg for children aged 6 to <18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.; Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to <18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.; Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.; Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to <12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to <18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of ≥4 despite loratadine and mometasone furoate nasal spray.; Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants aged 5 to <18 years with asthma symptoms .; Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of 2 inhalations twice daily among participants aged 12 to <18 years up to a maximum dose of 10 inhalations twice daily, in combination with albuterol, among participants with ≥4 albuterol sulfate inhalations/day for 2 days as rescue medication for nocturnal asthma or shortness of breath.; Prednisone tablet 5 mg was administered orally at a dose of 1 mg/kg/day once daily up to a maximum of 50 mg/day on Day 1, and at a dose of 0.5 mg/kg/day once daily up to a maximum of 25 mg/day on Days 2, 3, 5, and 7 as rescue medication for asthma exacerbation at the discretion of the investigator.
Other intervention name(s): Phleum pratense extract; Claritin; Claritin; Pantanol; Nasonex; Proventil; Ventolin; Volmax; Vospire; Flonase; Deltasone; Meticorten; Orasone; Prednicen-M; Prednicot; Sterapred; Sterapred DS
Intervention MeSH terms: Fluticasone; Mometasone Furoate; Loratadine; Olopatadine Hydrochloride; Prednisone; Albuterol
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: rhinoconjunctivitis; rhinitis; conjunctivitis; allergy; allergen; immunotherapy